drugset
drugset / Trial / NCT04221360

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375

NCT04221360 ↗

Phase 1 Unknown 26 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-375.

Timeline

Start
2020-01-29
Primary completion
2020-03-06
Completion
2020-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-375 Unknown — Oral
Subject D390 Unknown — Oral

Indications

type 2 diabetes mellitus